vs
Side-by-side financial comparison of Claritev Corp (CTEV) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $185.2M, roughly 1.3× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -32.7%, a 33.6% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 2.5%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CTEV vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $185.2M |
| Net Profit | $-80.6M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | -3.1% | 8.6% |
| Net Margin | -32.7% | 0.9% |
| Revenue YoY | 6.2% | 23.7% |
| Net Profit YoY | 41.6% | -88.5% |
| EPS (diluted) | $-4.88 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $185.2M | ||
| Q3 25 | $246.0M | $169.1M | ||
| Q2 25 | $241.6M | $154.7M | ||
| Q1 25 | $231.3M | $125.2M | ||
| Q4 24 | $232.1M | $149.7M | ||
| Q3 24 | $230.5M | $141.5M | ||
| Q2 24 | $233.5M | $126.7M | ||
| Q1 24 | $234.5M | $110.4M |
| Q4 25 | $-80.6M | $1.7M | ||
| Q3 25 | $-69.8M | $17.3M | ||
| Q2 25 | $-62.6M | $-24.4M | ||
| Q1 25 | $-71.3M | $-21.7M | ||
| Q4 24 | $-138.0M | $14.7M | ||
| Q3 24 | $-391.4M | $-6.7M | ||
| Q2 24 | $-576.7M | $-15.7M | ||
| Q1 24 | $-539.7M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | -3.1% | 8.6% | ||
| Q3 25 | 4.1% | 20.3% | ||
| Q2 25 | 6.9% | -6.1% | ||
| Q1 25 | 4.2% | -6.3% | ||
| Q4 24 | -17.8% | 10.7% | ||
| Q3 24 | -146.7% | 15.3% | ||
| Q2 24 | -224.4% | 11.8% | ||
| Q1 24 | -207.4% | -25.1% |
| Q4 25 | -32.7% | 0.9% | ||
| Q3 25 | -28.4% | 10.2% | ||
| Q2 25 | -25.9% | -15.8% | ||
| Q1 25 | -30.8% | -17.3% | ||
| Q4 24 | -59.4% | 9.8% | ||
| Q3 24 | -169.8% | -4.8% | ||
| Q2 24 | -247.0% | -12.4% | ||
| Q1 24 | -230.1% | -43.9% |
| Q4 25 | $-4.88 | $0.00 | ||
| Q3 25 | $-4.23 | $0.06 | ||
| Q2 25 | $-3.81 | $-0.08 | ||
| Q1 25 | $-4.38 | $-0.07 | ||
| Q4 24 | $-8.49 | $0.05 | ||
| Q3 24 | $-24.25 | $-0.02 | ||
| Q2 24 | $-35.78 | $-0.05 | ||
| Q1 24 | $-33.40 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $293.5M |
| Total DebtLower is stronger | $4.6B | $392.7M |
| Stockholders' EquityBook value | $-173.9M | $274.2M |
| Total Assets | $4.9B | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $293.5M | ||
| Q3 25 | $39.2M | $263.8M | ||
| Q2 25 | $56.4M | $231.0M | ||
| Q1 25 | $23.1M | $250.6M | ||
| Q4 24 | $16.8M | $249.9M | ||
| Q3 24 | $86.6M | $249.8M | ||
| Q2 24 | $48.8M | $260.1M | ||
| Q1 24 | $58.7M | $239.6M |
| Q4 25 | $4.6B | $392.7M | ||
| Q3 25 | $4.5B | $392.0M | ||
| Q2 25 | $4.5B | $391.3M | ||
| Q1 25 | $4.5B | $390.7M | ||
| Q4 24 | $4.5B | $390.1M | ||
| Q3 24 | $4.5B | $389.5M | ||
| Q2 24 | $4.5B | $388.9M | ||
| Q1 24 | $4.5B | $388.4M |
| Q4 25 | $-173.9M | $274.2M | ||
| Q3 25 | $-101.8M | $230.4M | ||
| Q2 25 | $-39.9M | $204.3M | ||
| Q1 25 | $14.8M | $193.6M | ||
| Q4 24 | $84.0M | $194.0M | ||
| Q3 24 | $207.6M | $178.8M | ||
| Q2 24 | $603.4M | $132.5M | ||
| Q1 24 | $1.2B | $130.7M |
| Q4 25 | $4.9B | $949.9M | ||
| Q3 25 | $5.0B | $868.8M | ||
| Q2 25 | $5.1B | $815.3M | ||
| Q1 25 | $5.1B | $789.8M | ||
| Q4 24 | $5.2B | $785.0M | ||
| Q3 24 | $5.3B | $786.6M | ||
| Q2 24 | $5.7B | $749.5M | ||
| Q1 24 | $6.4B | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | 304.87× | 2.02× | ||
| Q4 24 | 53.67× | 2.01× | ||
| Q3 24 | 21.73× | 2.18× | ||
| Q2 24 | 7.48× | 2.93× | ||
| Q1 24 | 3.85× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $16.3M |
| Free Cash FlowOCF − Capex | $36.4M | $16.0M |
| FCF MarginFCF / Revenue | 14.8% | 8.6% |
| Capex IntensityCapex / Revenue | 12.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $16.3M | ||
| Q3 25 | $19.9M | $35.7M | ||
| Q2 25 | $61.2M | $-26.5M | ||
| Q1 25 | $-30.1M | $7.8M | ||
| Q4 24 | $-33.4M | $-3.9M | ||
| Q3 24 | $72.8M | $-23.0M | ||
| Q2 24 | $18.5M | $22.7M | ||
| Q1 24 | $49.7M | $-29.7M |
| Q4 25 | $36.4M | $16.0M | ||
| Q3 25 | $-16.3M | $35.3M | ||
| Q2 25 | $36.6M | $-28.9M | ||
| Q1 25 | $-68.9M | $7.5M | ||
| Q4 24 | $-63.8M | $-4.2M | ||
| Q3 24 | $41.1M | $-23.3M | ||
| Q2 24 | $-7.0M | $21.6M | ||
| Q1 24 | $19.2M | $-31.5M |
| Q4 25 | 14.8% | 8.6% | ||
| Q3 25 | -6.6% | 20.9% | ||
| Q2 25 | 15.2% | -18.7% | ||
| Q1 25 | -29.8% | 6.0% | ||
| Q4 24 | -27.5% | -2.8% | ||
| Q3 24 | 17.8% | -16.5% | ||
| Q2 24 | -3.0% | 17.0% | ||
| Q1 24 | 8.2% | -28.5% |
| Q4 25 | 12.1% | 0.2% | ||
| Q3 25 | 14.7% | 0.2% | ||
| Q2 25 | 10.2% | 1.6% | ||
| Q1 25 | 16.8% | 0.2% | ||
| Q4 24 | 13.1% | 0.2% | ||
| Q3 24 | 13.8% | 0.3% | ||
| Q2 24 | 10.9% | 0.9% | ||
| Q1 24 | 13.0% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
